Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Althea Technologies has spun-out an independent company to commercialize its breakthrough genetic testing technology through a variety of laboratory services and gene expression products for use in monitoring and managing cancer treatment.
Subscribe to our email newsletter
The Althea Diagnostics spin-out incorporates a test for differential diagnosis of pediatric solid-tumors, along with a pipeline of other biomarker sets that will be used for cancer management. In addition, the company will continue to provide laboratory services for biopharmaceutical companies and contract research organizations, including the Express Pathway service suite, which is currently utilized by drug developers to identify promising molecules, explore treatment pathways or build marker sets of clinical utility.
Althea Diagnostics will build upon commercialized proprietary technology for quantitative measurement of multiple genes in a single reaction, as well as new technologies and bioinformatics applications designed to speed development of valuable molecular diagnostic tests. The company will be located within Althea’s San Diego campus.